Literature DB >> 16359163

Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.

Steven M Johnson1, R Luke Wiseman, Yoshiki Sekijima, Nora S Green, Sara L Adamski-Werner, Jeffery W Kelly.   

Abstract

Small molecule-mediated protein stabilization inside or outside of the cell is a promising strategy to treat protein misfolding/misassembly diseases. Herein we focus on the transthyretin (TTR) amyloidoses and demonstrate that preferential ligand binding to and stabilization of the native state over the dissociative transition state raises the kinetic barrier of dissociation (rate-limiting for amyloidogenesis), slowing and in many cases preventing TTR amyloid fibril formation. Since T119M-TTR subunit incorporation into tetramers otherwise composed of disease-associated subunits also imparts kinetic stability on the tetramer and ameliorates amyloidosis in humans, it is likely that small molecule-mediated native state kinetic stabilization will also alleviate TTR amyloidoses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16359163     DOI: 10.1021/ar020073i

Source DB:  PubMed          Journal:  Acc Chem Res        ISSN: 0001-4842            Impact factor:   22.384


  101 in total

1.  Discovery and characterization of a mammalian amyloid disaggregation activity.

Authors:  Amber N Murray; James P Solomon; Ya-Juan Wang; William E Balch; Jeffery W Kelly
Journal:  Protein Sci       Date:  2010-04       Impact factor: 6.725

2.  A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate.

Authors:  Sungwook Choi; Derrick Sek Tong Ong; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-10-21       Impact factor: 15.419

3.  Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion.

Authors:  Steve Bourgault; James P Solomon; Natàlia Reixach; Jeffery W Kelly
Journal:  Biochemistry       Date:  2011-01-24       Impact factor: 3.162

4.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Authors:  Christine E Bulawa; Stephen Connelly; Michael Devit; Lan Wang; Charlotte Weigel; James A Fleming; Jeff Packman; Evan T Powers; R Luke Wiseman; Theodore R Foss; Ian A Wilson; Jeffery W Kelly; Richard Labaudinière
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

5.  Protein folding: then and now.

Authors:  Yiwen Chen; Feng Ding; Huifen Nie; Adrian W Serohijos; Shantanu Sharma; Kyle C Wilcox; Shuangye Yin; Nikolay V Dokholyan
Journal:  Arch Biochem Biophys       Date:  2007-06-08       Impact factor: 4.013

Review 6.  Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions.

Authors:  Leah N Makley; Jason E Gestwicki
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

7.  Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.

Authors:  Steven M Johnson; Stephen Connelly; Ian A Wilson; Jeffery W Kelly
Journal:  J Med Chem       Date:  2008-09-24       Impact factor: 7.446

8.  Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma.

Authors:  Sungwook Choi; Stephen Connelly; Natàlia Reixach; Ian A Wilson; Jeffery W Kelly
Journal:  Nat Chem Biol       Date:  2010-02       Impact factor: 15.040

9.  Differences in prion strain conformations result from non-native interactions in a nucleus.

Authors:  Yumiko Ohhashi; Kazuki Ito; Brandon H Toyama; Jonathan S Weissman; Motomasa Tanaka
Journal:  Nat Chem Biol       Date:  2010-01-17       Impact factor: 15.040

10.  Amyloidogenic potential of transthyretin variants: insights from structural and computational analyses.

Authors:  Laura Cendron; Antonio Trovato; Flavio Seno; Claudia Folli; Beatrice Alfieri; Giuseppe Zanotti; Rodolfo Berni
Journal:  J Biol Chem       Date:  2009-07-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.